US-based sterile injectable (pre-filled syringe) manufacturing facility focused on small-molecule generic 505b2 and 505j products.

Minimally-invasive nitinol implant delivered into prostatic urethra and indicated to re-open the prostatic urethra in BPH patients, restoring urinary flow.

HOW WE USE YOUR INFORMATION

to operate, manage, develop and promote our business and, in particular, our relationship with you and the organization you represent (if any) and related investments and/or transactions;
to operate, administer and improve our website and premises and other aspects of the way in which we conduct our operations;
to protect our business from fraud, money-laundering, breach of confidence, theft of proprietary materials and other financial or business crimes;

to send marketing communications to you, if applicable and
to comply with our legal and regulatory obligations and bring and defend legal claims.

We may review information about you that we maintain in our systems, including the contents of and information related to your emails and other communications with us, for compliance and business-protection purposes as described above. This may include reviews to disclose information relevant to litigation and/or reviews of records relevant to internal or external regulatory or criminal investigations. To the extent permitted by applicable law, these reviews will be conducted in a reasonable and proportionate way and approved at an appropriate level of management. They may ultimately involve the disclosure of your information to governmental agencies and litigation counterparties as described below. Your emails and other communications may occasionally be accessed by persons other than the staff member with whom they are exchanged for ordinary business management purposes (for example, where necessary when a staff member is out of the office or has left New Rhein). 

We will only use your personal information for the purposes for which we collected it, unless we reasonably consider that we need to use it for another reason and that reason is compatible with the original purpose. If you wish to get an explanation as to how the processing for the new purpose is compatible with the original purpose, please contact us.

If we need to use your personal information for an unrelated purpose, we will notify you and we will explain the legal basis which allows us to do so.

Modern Architecture

SHANKAR HARIHARAN, PHD

Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.

SHANKAR HARIHARAN, PHD

Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.

SHANKAR HARIHARAN, PHD

Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.

SHANKAR HARIHARAN, PHD

Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.

Daniel Parera, MD

Executive in Residence

Daniel is an entrepreneur, investor and advisor in the Life Science and Food industry. He co-founded three companies and previously was an Executive-in-Residence at TVM Capital Life Science in Munich for almost 4 years - amongst reviewing several hundred opportunities a year worldwide, closing a large pre-IPO investment with subsequent IPO, serving on the Board of Directors of three portfolio companies, and as part of new fund raising was instrumental for the first closing with a key European strategic investor. He had joined TVM from Novartis, where he spent 12 years in various line function roles across three Divisions including Global Franchise Head Strategic Marketing for Immunology & Infectious Diseases, Pharma in Basel, Switzerland, Global Head of Development, Diagnostics for Vaccines & Diagnostics in Emeryville, CA, USA and Global Head New Product & Portfolio Strategy Biopharmaceuticals for Sandoz in Holzkirchen / Munich, Germany. There he oversaw and was a team member for multiple collaborations, licensing deals and acquisitions from academic to multi-billion dollar transactions, world-wide commercial launches and FDA / EMA / CFDA / ANVISA registrations with respective global clinical trials. Prior to Novartis he was at McKinsey & Company, Inc., was trained as an MD from Johannes-Gutenberg-University Mainz, Germany with clinical training in Germany, Switzerland and the USA (UC Davis Medical Center, Sacramento, CA) and was a scientific co-worker at the Institute for Occupational, Social and Environmental Medicine in Mainz for several years.